- Home
- Publications
- Publication Search
- Publication Details
Title
KRAS G12C–Mutant Non–Small Cell Lung Cancer
Authors
Keywords
-
Journal
JOURNAL OF MOLECULAR DIAGNOSTICS
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-02-21
DOI
10.1016/j.jmoldx.2021.02.002
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The prevalence of KRASG12C mutations utilizing circulating tumor DNA (ctDNA) in 80,911 patients with cancer.
- (2020) Kyaw Thein et al. JOURNAL OF CLINICAL ONCOLOGY
- Pulmonary toxicity of systemic lung cancer therapy
- (2020) Kathryn Long et al. RESPIROLOGY
- Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer
- (2020) Matthew J. LaMarche et al. JOURNAL OF MEDICINAL CHEMISTRY
- KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors
- (2020) David S. Hong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Discovery of potent SOS1 inhibitors that block RAS activation via disruption of the RAS–SOS1 interaction
- (2019) Roman C. Hillig et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Updates Regarding Biomarker Testing for Non–Small Cell Lung Cancer: Considerations from the National Lung Cancer Roundtable
- (2019) Edward S. Kim et al. Journal of Thoracic Oncology
- Next-Generation Sequencing (NGS) Methods Show Superior or Equivalent Performance to Non-NGS Methods on BRAF, EGFR, and KRAS Proficiency Testing Samples
- (2019) Lea F. Surrey et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- A phase I/II multiple expansion cohort trial of MRTX849 in patients with advanced solid tumors with KRAS G12C mutation.
- (2019) Kyriakos P. Papadopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways
- (2019) Matthias Scheffler et al. Journal of Thoracic Oncology
- Rapid clinical mutational testing of KRAS, BRAF and EGFR: a prospective comparative analysis of the Idylla technique with high-throughput next-generation sequencing
- (2019) Matthias Van Haele et al. JOURNAL OF CLINICAL PATHOLOGY
- KRAS and Immune Checkpoint Inhibitors—Serendipity Raising Expectations
- (2019) Sacha I. Rothschild Journal of Thoracic Oncology
- Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey
- (2019) Jeffrey P. Gregg et al. Translational Lung Cancer Research
- Standardization of Sequencing Coverage Depth in NGS: Recommendation for Detection of Clonal and Subclonal Mutations in Cancer Diagnostics
- (2019) Anna Petrackova et al. Frontiers in Oncology
- New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness
- (2019) Haitang Yang et al. Frontiers in Oncology
- Therapeutic targeting of RAS: New hope for drugging the “undruggable”
- (2019) Imran Khan et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
- The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
- (2019) Jude Canon et al. NATURE
- High-intensity sequencing reveals the sources of plasma circulating cell-free DNA variants
- (2019) Pedram Razavi et al. NATURE MEDICINE
- Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence
- (2019) Samuel J. Klempner et al. ONCOLOGIST
- Rapid On-Site Evaluation of Endobronchial Ultrasound–Guided Transbronchial Needle Aspirations for the Diagnosis of Lung Cancer: A Perspective From Members of the Pulmonary Pathology Society
- (2018) Deepali Jain et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
- (2018) Neal I. Lindeman et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- TP53,STK11andEGFRMutations Predict Tumor Immune Profile and the Response to anti-PD-1 in Lung Adenocarcinoma
- (2018) Jerome Biton et al. CLINICAL CANCER RESEARCH
- The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients
- (2018) Oliver A. Zill et al. CLINICAL CANCER RESEARCH
- Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS G12C-Driven Mouse Model of Lung Cancer
- (2018) Shuai Li et al. CLINICAL CANCER RESEARCH
- False positive plasma genotyping due to clonal hematopoiesis
- (2018) Yuebi Hu et al. CLINICAL CANCER RESEARCH
- Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update
- (2018) Gregory P. Kalemkerian et al. JOURNAL OF CLINICAL ONCOLOGY
- Validity of Targeted Next-Generation Sequencing in Routine Care for Identifying Clinically Relevant Molecular Profiles in Non–Small-Cell Lung Cancer
- (2018) Antoine Legras et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- IASLC Statement Paper: Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC)
- (2018) Christian Rolfo et al. Journal of Thoracic Oncology
- KRAS -Mutant Non-Small Cell Lung Cancer: From Biology to Therapy
- (2018) Irene Ferrer et al. LUNG CANCER
- STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
- (2018) Ferdinandos Skoulidis et al. Cancer Discovery
- EGFR–TKI-Associated Interstitial Pneumonitis in Nivolumab-Treated Patients With Non–Small Cell Lung Cancer
- (2018) Yasuo Oshima et al. JAMA Oncology
- Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma
- (2018) Chee Khoon Lee et al. JAMA Oncology
- Molecular testing and treatment patterns for patients with advanced non-small cell lung cancer: PIvOTAL observational study
- (2018) Dae Ho Lee et al. PLoS One
- Real-world EGFR testing in patients with stage IIIB/IV non-small-cell lung cancer in North China: A multicenter, non-interventional study
- (2018) Ying Cheng et al. Thoracic Cancer
- Long-peptide vaccination with driver gene mutations in p53 and Kras induces cancer mutation-specific effector as well as regulatory T cell responses
- (2018) Jasmin Quandt et al. OncoImmunology
- SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
- (2018) Mingxia Zhao et al. Acta Pharmaceutica Sinica B
- Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing–Based Oncology Assays
- (2018) Jason D. Merker et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Therapeutic strategies to target RAS-mutant cancers
- (2018) Meagan B. Ryan et al. Nature Reviews Clinical Oncology
- Impact of RAS mutation subtype on clinical outcome—a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer
- (2018) Marcel Wiesweg et al. ONCOGENE
- EGFR Mutation Testing: Changing Patterns of Molecular Testing in Brazil
- (2018) Sofia Palacio et al. ONCOLOGIST
- Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non–Small Cell Lung Cancer
- (2017) Pasi A. Jänne et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
- (2017) Leora Horn et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies
- (2017) Emmet J. Jordan et al. Cancer Discovery
- AACR Project GENIE: Powering Precision Medicine through an International Consortium
- (2017) Cancer Discovery
- Kras and Tumor Immunity: Friend or Foe?
- (2017) Jane Cullis et al. Cold Spring Harbor Perspectives in Medicine
- Progress and prospects of early detection in lung cancer
- (2017) Sean Blandin Knight et al. Open Biology
- Genomic Analysis of Plasma Cell-Free DNA in Patients With Cancer
- (2017) Geoffrey R. Oxnard et al. JAMA Oncology
- Clinical utility of circulating cell-free DNA in advanced colorectal cancer
- (2017) Allan A. Lima Pereira et al. PLoS One
- Optimizing Workflows and Processing of Cytologic Samples for Comprehensive Analysis by Next-Generation Sequencing: Memorial Sloan Kettering Cancer Center Experience
- (2016) Shaozhou Ken Tian et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling
- (2016) Sai Krishna Athuluri-Divakar et al. CELL
- Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma
- (2016) Zhong-Yi Dong et al. CLINICAL CANCER RESEARCH
- Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
- (2016) Jonathan M. L. Ostrem et al. NATURE REVIEWS DRUG DISCOVERY
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical Versus Research Sequencing
- (2016) Yuriy Shevchenko et al. Cold Spring Harbor Perspectives in Medicine
- Inhibitors of Ras-SOS Interactions
- (2015) Shaoyong Lu et al. ChemMedChem
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
- (2015) Donavan T. Cheng et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Prognostic Impact of KRAS Mutation Subtypes in 677 Patients with Metastatic Lung Adenocarcinomas
- (2015) Helena A. Yu et al. Journal of Thoracic Oncology
- Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations
- (2015) J. C. Hunter et al. MOLECULAR CANCER RESEARCH
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group
- (2015) Manfred Dietel et al. THORAX
- Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors
- (2015) Q. J. Wang et al. Cancer Immunology Research
- KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma
- (2014) Ernest Nadal et al. Journal of Thoracic Oncology
- Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
- (2014) M. Macerelli et al. LUNG CANCER
- Drugging the undruggable RAS: Mission Possible?
- (2014) Adrienne D. Cox et al. NATURE REVIEWS DRUG DISCOVERY
- Sequencing depth and coverage: key considerations in genomic analyses
- (2014) David Sims et al. NATURE REVIEWS GENETICS
- The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells
- (2014) Makoto Wada et al. PLoS One
- Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA
- (2014) D. A. Haber et al. Cancer Discovery
- Pooled Analysis of the Prognostic and Predictive Effects ofKRASMutation Status andKRASMutation Subtype in Early-Stage Resected Non–Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy
- (2013) Frances A. Shepherd et al. JOURNAL OF CLINICAL ONCOLOGY
- The relationship between KRAS gene mutations and HLA class I antigen downregulation in the metastasis of non-small cell lung cancer
- (2013) Xiao-Peng He et al. JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
- K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
- (2013) Jonathan M. Ostrem et al. NATURE
- A Comprehensive Survey of Ras Mutations in Cancer
- (2012) I. A. Prior et al. CANCER RESEARCH
- Molecular Epidemiology of EGFR and KRAS Mutations in 3,026 Lung Adenocarcinomas: Higher Susceptibility of Women to Smoking-Related KRAS-Mutant Cancers
- (2012) S. Dogan et al. CLINICAL CANCER RESEARCH
- Personalized Medicine for Non–Small-Cell Lung Cancer: Implications of Recent Advances in Tissue Acquisition for Molecular and Histologic Testing
- (2012) Andre L. Moreira et al. Clinical Lung Cancer
- Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome
- (2012) Nathan T. Ihle et al. JNCI-Journal of the National Cancer Institute
- A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations
- (2011) Gregory J. Riely et al. Journal of Thoracic Oncology
- Rapid On-site Evaluation of Transbronchial Aspirates in the Diagnosis of Hilar and Mediastinal Adenopathy
- (2010) Rocco Trisolini et al. CHEST
- Frequency and Distinctive Spectrum of KRAS Mutations in Never Smokers with Lung Adenocarcinoma
- (2008) G. J. Riely et al. CLINICAL CANCER RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now